GLRX3

Across TCGA pan-cancer cohorts, GLRX3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GLRX3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GLRX3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLRX3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where GLRX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	1.000	0.893	<.001	23	view →
LUAD	DFS	Median	II,III,IV	0.176	0.733	.003	22	view →
GBM	OS	Tertile	All	0.462	0.703	.005	12	view →
PDAC	DFS	Tertile	III,IV	0.232	0.465	.016	10	view →
CCRCC	DFS	Quartile	III,IV	0.248	0.654	.002	8	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.250	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GLRX3–HNSC (DFS)

Open the HNSC breakdown →